logo
Plus   Neg
Share
Email

Ventas Issues FY20 Earnings Guidance - Quick Facts

Ventas, Inc. (VTR) said, for 2020, the company projects net income per share in a range of $1.61 to $1.74. Analysts polled by Thomson Reuters expect the company to report profit per share of $1.16. Analysts' estimates typically exclude special items. Nareit FFO is anticipated in the range of $3.79 to $3.94, and normalized FFO is projected to be in the range of $3.56 to $3.69.

Fourth quarter earnings per share was $0.03 compared to $0.17, a year ago. On average, eight analysts polled by Thomson Reuters expected the company to report profit per share of $0.27, for the quarter. Nareit FFO per share improved to $0.94 from $0.81. Normalized FFO per share was $0.93 compared to $0.96.

Fourth-quarter total revenues increased to $996.00 million from $923.26 million. Analysts expected revenue of $969.78 million for the quarter. Quarterly same-store total property portfolio cash net operating income declined 0.6 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
RELATED NEWS
Follow RTT